{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T03:19:07Z","timestamp":1792293547591,"version":"4.4.0"},"reference-count":64,"publisher":"Bioscientifica","issue":"3","content-domain":{"domain":["erc.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,3]]},"abstract":"<jats:p>Carcinoid syndrome (CS) is a debilitating disease caused by functional neuroendocrine tumors. Several treatment options are available to alleviate the hormonal symptoms, but their relative efficacy is unknown. Online databases were searched for publications on the treatment of CS symptoms. Independent reviewers assessed relevant publications for study quality and outcome. Meta-analysis of the outcomes of the intervention on CS-related symptoms was stratified by the type of treatment. We found 3682 therapeutic interventions on CS-specific outcomes were collected from 93 studies. Overall, the study qualities were poor with only six randomized controlled clinical trials. The somatostatin analogs octreotide and lanreotide induced symptomatic improvement in 65\u201372% and biochemical response in 45\u201346% of patients. An increase in dose or frequency or interclass switch led to a reduction of flushes and\/or diarrhea in 72\u201384% of cases. Retrospective, institutional series showed that liver-directed therapy can improve symptoms in 82% of CS patients with a liver-dominant disease. The serotonin synthesis inhibitor telotristat ethyl reduced bowel movements in 40% of patients with diarrhea refractory to somatostatin analogs. Interferon-alpha controlled CS symptoms in 45\u201363% of cases. Favorable response has been noted after radionuclide therapy in subgroup analyses of studies not specifically involving CS patients. Chemotherapy and everolimus did not induce a significant response in the CS. We conclude that several treatment lines can be offered to patients suffering from the carcinoid syndrome. Initiation of randomized controlled trials with a primary outcome on carcinoid syndrome symptoms is strongly recommended.<\/jats:p>","DOI":"10.1530\/erc-18-0495","type":"journal-article","created":{"date-parts":[[2019,1,3]],"date-time":"2019-01-03T10:39:46Z","timestamp":1546511986000},"page":"R145-R156","update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-8","source":"Crossref","is-referenced-by-count":73,"title":["Management of carcinoid syndrome: a systematic review and meta-analysis"],"prefix":"10.1530","volume":"26","author":[{"given":"Johannes","family":"Hofland","sequence":"first","affiliation":[{"name":"1ENETS Center of Excellence, Section of Endocrinology, Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aura D","family":"Herrera-Mart\u00ednez","sequence":"additional","affiliation":[{"name":"1ENETS Center of Excellence, Section of Endocrinology, Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands"},{"name":"2Maimonides Institute for Biomedical Research of Cordoba (IMIBIC), C\u00f3rdoba, Spain"},{"name":"3Endocrinology and Nutrition Service, Reina Sofia University Hospital, C\u00f3rdoba, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter T","family":"Zandee","sequence":"additional","affiliation":[{"name":"1ENETS Center of Excellence, Section of Endocrinology, Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter W","family":"de Herder","sequence":"additional","affiliation":[{"name":"1ENETS Center of Excellence, Section of Endocrinology, Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","reference":[{"key":"ref331","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/1097-0142(19910101)67:1<33::AID-CNCR2820670107>3.0.CO;2-E","article-title":"A study of cyproheptadine in the treatment of metastatic carcinoid tumor and the malignant carcinoid syndrome","volume":"67","year":"1991","journal-title":"Cancer"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJMoa1316158","article-title":"Lanreotide in metastatic enteropancreatic neuroendocrine tumors","volume":"371","year":"2014","journal-title":"New England Journal of Medicine"},{"key":"ref581","first-page":"107","article-title":"High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours","volume":"151","year":"2004","journal-title":"European Journal of Endocrinology"},{"key":"ref391","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJM198307213090301","article-title":"Effects of leukocyte interferon on clinical symptoms and hormone levels in patients with mid-gut carcinoid tumors and carcinoid syndrome","volume":"309","year":"1983","journal-title":"New England Journal of Medicine"},{"key":"ref131","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1159\/000007693","article-title":"Ultra-high-dose lanreotide treatment in patients with metastatic neuroendocrine gastroenteropancreatic tumors","volume":"60","year":"1999","journal-title":"Digestion"},{"key":"ref301","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1136\/bmj.287.6397.932","article-title":"Role of hepatic arterial embolisation in the carcinoid syndrome","volume":"287","year":"1983","journal-title":"BMJ"},{"key":"ref261","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1200\/JCO.2016.69.2780","article-title":"Telotristat ethyl, a tryptophan hydroxylase inhibitor for the treatment of carcinoid syndrome","volume":"35","year":"2017","journal-title":"Journal of Clinical Oncology"},{"key":"ref511","first-page":"523","article-title":"Hepatic dearterialization in the treatment of carcinoid syndrome","volume":"153","year":"1987","journal-title":"Acta Chirurgica Scandinavica"},{"key":"ref181","year":"2011","journal-title":"Cochrane Handbook for Systematic Reviews of Interventions, 5.1.0 Version"},{"key":"ref231","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2036.2011.04693.x","article-title":"Long-term results of treatment of malignant carcinoid syndrome with prolonged release lanreotide (somatuline autogel)","volume":"34","year":"2011","journal-title":"Alimentary Pharmacology and Therapeutics"},{"key":"ref641","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1530\/EJE-16-0392","article-title":"Limited value for urinary 5-HIAA excretion as prognostic marker in gastrointestinal neuroendocrine tumours","volume":"175","year":"2016","journal-title":"European Journal of Endocrinology"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations","volume":"328","year":"2004","journal-title":"BMJ"},{"key":"ref521","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1634\/theoncologist.2014-0120","article-title":"Clinical benefits of above-standard dose of octreotide LAR in patients with neuroendocrine tumors for control of carcinoid syndrome symptoms: a multicenter retrospective chart review study.","volume":"19","year":"2014","journal-title":"Oncologist"},{"key":"ref621","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","year":"2011","journal-title":"New England Journal of Medicine"},{"key":"ref311","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1365-2036.2009.04174.x","article-title":"Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours.","volume":"31","year":"2010","journal-title":"Alimentary Pharmacology and Therapeutics"},{"key":"ref461","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group","volume":"27","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"ref171","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1470-2045(17)30110-9","article-title":"Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study.","volume":"18","year":"2017","journal-title":"Lancet Oncology"},{"key":"ref221","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1080\/13696998.2017.1387120","article-title":"Cost-effectiveness analysis of telotristat ethyl for treatment of carcinoid syndrome diarrhea inadequately controlled with somatostatin analogs","volume":"21","year":"2018","journal-title":"Journal of Medical Economics"},{"key":"ref351","doi-asserted-by":"crossref","first-page":"445","DOI":"10.3109\/02841868909111220","article-title":"Interferon treatment in patients with malignant carcinoids","volume":"28","year":"1989","journal-title":"Acta Oncologica"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1365-2036.1988.tb00684.x","article-title":"The effects of the 5-hydroxytryptamine (5HT3) receptor antagonist ICS 205\u2013930 in the carcinoid syndrome","volume":"2","year":"1988","journal-title":"Alimentary Pharmacology and Therapeutics"},{"key":"ref571","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.4158\/EP151172.OR","article-title":"Evaluation of lanreotide depot\/autogel efficacy and safety as a carcinoid syndrome treatment (elect): a randomized, double-blind, placebo-controlled trial","volume":"22","year":"2016","journal-title":"Endocrine Practice"},{"key":"ref191","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1210\/er.2000-0001","article-title":"The pathophysiological consequences of somatostatin receptor internalization and resistance","volume":"24","year":"2003","journal-title":"Endocrine Reviews"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.3748\/wjg.v21.i6.1945","article-title":"Gastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR: a systematic literature review.","volume":"21","year":"2015","journal-title":"World Journal of Gastroenterology"},{"key":"ref281","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1200\/JCO.2007.15.2553","article-title":"Treatment with the radiolabeled somatostatin analog (177 Lu-DOTA 0,Tyr3)octreotate: toxicity, efficacy, and survival","volume":"26","year":"2008","journal-title":"Journal of Clinical Oncology"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/BF01655111","article-title":"Somatostatin analog sandostatin and inhibition of tumor growth in patients with metastatic endocrine gastroenteropancreatic tumors","volume":"17","year":"1993","journal-title":"World Journal of Surgery"},{"key":"ref161","first-page":"CD010335","article-title":"Somatostatin analogues for carcinoid syndrome (protocol)","volume":"2","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"ref551","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1590\/S0004-27302005000500028","article-title":"Carcinoid syndrome: diagnosis and medical management.","volume":"49","year":"2005","journal-title":"Arquivos Brasileiros de Endocrinologia e Metabologia"},{"key":"ref471","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1200\/JCO.1999.17.2.600","article-title":"Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome","volume":"17","year":"1999","journal-title":"Journal of Clinical Oncology"},{"key":"ref561","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/0959-8049(92)90389-J","article-title":"A dose-escalation study of recombinant interferon-alpha in patients with a metastatic carcinoid tumour","volume":"28","year":"1992","journal-title":"European Journal of Cancer"},{"key":"ref241","article-title":"Oral ondansetron offers effective antidiarrheal activity for carcinoid syndrome refractory to somatostatin analogs","year":"2018","journal-title":"Oncologist"},{"key":"ref371","first-page":"514","article-title":"Release of a kinin peptide in the carcinoid syndrome","volume":"1","year":"1964","journal-title":"Lancet"},{"key":"ref141","first-page":"326","article-title":"Shortened interval of long-acting octreotide administration is effective in patients with well-differentiated neuroendocrine carcinomas in progression on standard doses","volume":"35","year":"2012","journal-title":"Journal of Endocrinological Investigation"},{"key":"ref611","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S0959-8049(98)00009-4","article-title":"Effects of ondansetron on gastrointestinal symptoms in carcinoid syndrome","volume":"34","year":"1998","journal-title":"European Journal of Cancer"},{"key":"ref631","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","article-title":"Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study","volume":"387","year":"2016","journal-title":"Lancet"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/S0002-9610(98)00042-7","article-title":"Hepatic artery chemoembolization for management of patients with advanced metastatic carcinoid tumors","volume":"175","year":"1998","journal-title":"American Journal of Surgery"},{"key":"ref201","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/s41574-018-0082-5","article-title":"Role of biomarker tests for diagnosis of neuroendocrine tumours","volume":"14","year":"2018","journal-title":"Nature Reviews Endocrinology"},{"key":"ref481","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.dld.2015.12.013","article-title":"Patient-reported outcomes with lanreotide Autogel\/Depot for carcinoid syndrome: an international observational study","volume":"48","year":"2016","journal-title":"Digestive and Liver Disease"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/(SICI)1097-0142(19960115)77:2<402::AID-CNCR25>3.0.CO;2-4","article-title":"Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors \u2013 a study by the Italian Trials in Medical Oncology Group","volume":"77","year":"1996","journal-title":"Cancer"},{"key":"ref361","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1210\/jcem-63-3-605","article-title":"Tachykinins in carcinoid tumors: their use as a tumor marker and possible role in the carcinoid flush.","volume":"63","year":"1986","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref531","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors","volume":"376","year":"2017","journal-title":"New England Journal of Medicine"},{"key":"ref541","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/MPA.0000000000000850","article-title":"The North American Neuroendocrine Tumor Society consensus guidelines for surveillance and medical management of midgut neuroendocrine tumors","volume":"46","year":"2017","journal-title":"Pancreas"},{"key":"ref421","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000443167","article-title":"Enets consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site","volume":"103","year":"2016","journal-title":"Neuroendocrinology"},{"key":"ref491","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1136\/gut.42.5.628","article-title":"Medium-term effects of a new 5HT3 antagonist, alosetron, in patients with carcinoid diarrhoea","volume":"42","year":"1998","journal-title":"Gut"},{"key":"ref01","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1002\/cam4.435","article-title":"Association of dose escalation of octreotide long-acting release on clinical symptoms and tumor markers and response among patients with neuroendocrine tumors","volume":"4","year":"2015","journal-title":"Cancer Medicine"},{"key":"ref321","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1200\/JCO.1989.7.7.865","article-title":"Therapy of metastatic carcinoid tumor and the malignant carcinoid syndrome with recombinant leukocyte A interferon","volume":"7","year":"1989","journal-title":"Journal of Clinical Oncology"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1097\/MPA.0b013e31821f66b4","article-title":"Evaluating the characteristics and the management of patients with neuroendocrine tumors receiving octreotide LAR during a 6-year period","volume":"40","year":"2011","journal-title":"Pancreas"},{"key":"ref151","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1136\/gut.11.2.189","article-title":"Progress report: the carcinoid syndrome","volume":"11","year":"1970","journal-title":"Gut"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJM196711232772101","article-title":"Inhibition of serotonin synthesis by para-chlorophenylalanine in patients with the carcinoid syndrome","volume":"277","year":"1967","journal-title":"New England Journal of Medicine"},{"key":"ref381","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1159\/000051862","article-title":"Interferon in the management of neuroendocrine GEP-tumors: a review","volume":"62","year":"2000","journal-title":"Digestion"},{"key":"ref431","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1530\/ERC-17-0455","article-title":"Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial","volume":"25","year":"2018","journal-title":"Endocrine-Related Cancer"},{"key":"ref411","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(11)61742-X","article-title":"Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study","volume":"378","year":"2011","journal-title":"Lancet"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s12672-015-0233-2","article-title":"Symptomatic control of neuroendocrine tumours with everolimus","volume":"6","year":"2015","journal-title":"Hormones and Cancer"},{"key":"ref501","first-page":"440","article-title":"Ein fall von angioma teleangiectaticum cutis mit chronischer endocarditis und malignem d\u00fcnndarmcarcinoid","volume":"86","year":"1931","journal-title":"Beitrage Zur Pathologischen Anatomie"},{"key":"ref251","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1530\/ERC-14-0173","article-title":"Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide","volume":"21","year":"2014","journal-title":"Endocrine-Related Cancer"},{"key":"ref271","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1530\/ERC-11-0367","article-title":"Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study.","volume":"19","year":"2012","journal-title":"Endocrine-Related Cancer"},{"key":"ref451","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1177\/1758834016675803","article-title":"Refractory carcinoid syndrome: a review of treatment options.","volume":"9","year":"2017","journal-title":"Therapeutic Advances in Medical Oncology"},{"key":"ref401","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/(SICI)1097-0142(20000215)88:4<770::AID-CNCR6>3.0.CO;2-0","article-title":"Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance","volume":"88","year":"2000","journal-title":"Cancer"},{"key":"ref601","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jclinane.2016.03.008","article-title":"Development of effective prophylaxis against intraoperative carcinoid crisis","volume":"32","year":"2016","journal-title":"Journal of Clinical Anesthesia"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S1542-3565(05)00481-7","article-title":"Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial","volume":"3","year":"2005","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/annonc\/mdq670","article-title":"Control of carcinoid syndrome with everolimus","volume":"22","year":"2011","journal-title":"Annals of Oncology"},{"key":"ref211","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1111\/jgh.13752","article-title":"Single-institution experience of radioembolization with yttrium-90 microspheres for unresectable metastatic neuroendocrine liver tumors","volume":"32","year":"2017","journal-title":"Journal of Gastroenterology and Hepatology"},{"key":"ref441","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1016\/0140-6736(92)91235-Z","article-title":"Ondansetron in carcinoid syndrome","volume":"339","year":"1992","journal-title":"Lancet"},{"key":"ref291","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1186\/1471-2407-13-427","article-title":"Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: a Spanish, multicentre, open-label, single arm phase II study","volume":"13","year":"2013","journal-title":"BMC Cancer"},{"key":"ref341","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the Prisma statement","volume":"339","year":"2009","journal-title":"BMJ"}],"container-title":["Endocrine-Related Cancer"],"original-title":[],"link":[{"URL":"https:\/\/erc.bioscientifica.com\/view\/journals\/erc\/26\/3\/ERC-18-0495.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/erc.bioscientifica.com\/downloadpdf\/journals\/erc\/26\/3\/ERC-18-0495.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:55:09Z","timestamp":1784555709000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.bioscientifica.com\/erc\/article\/26\/3\/R145-R156\/25304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":64,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.1530\/erc-18-0495","relation":{},"ISSN":["1351-0088","1479-6821"],"issn-type":[{"value":"1351-0088","type":"print"},{"value":"1479-6821","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3]]}}}